Heart failure & cardiomyopathiesResearch article
First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure
- First-in-human study
Authors' conclusion
This first-in-human experience demonstrated that the implantation of an IVC sensor was safe and feasible.
Study context
- Population
- Heart failure (HF) patients with HF hospitalisation within the previous year, elevated natriuretic peptides, on optimal HF treatment49 contributed to primary endpoints
- Participants
- 50 patients
- Outcome
- Procedural success without device- or procedure-related complications (primary safety); signal acquisition following implantation and at a clinic visit (primary technical)
- Follow-up
- 3 months
Main finding
As reported in the abstract
Successful implantation
50 patients
Further findings
Agreement of sensor-derived inferior vena cava (IVC) area with CT
- Mean absolute error
- 13.53 mm² [3.55%]
- R2
- 0.98
Adherence to daily readings · 6 months
- Median adherence
- 96%
Exploratory clinical outcomes · 6 months
- Suggested improvements in NT-proBNP, NYHA class and quality of life and reduced HF events
- exploratory
Original publication
First-in-Human Implantable Inferior Vena Cava Sensor for Remote Care in Heart Failure. JACC Heart Fail. Published 9 April 2025. doi:10.1016/j.jchf.2025.01.019
Summarised from the published abstract; every number is checked against it